Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults

Completed · Phase 2 · Has a placebo group

Conditions studied: Sleep Apnea, Obstructive

In brief

In this protocol the investigators will test the effect of dalfampridine (a potassium channel blocker) on genioglossus muscle activity (EMG GG) during wakefulness and sleep in healthy control subjects.

Key facts

Study ID

NCT02656160

Run by

Brigham and Women's Hospital

People needed

13

Starts

2016-01-01

Expected to finish

2016-07-01

Last updated by the study team

2017-08-15

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy control subjects

You may not qualify if…

• Cardiovascular disease other than well controlled hypertension
• History of seizures

Where it is running

• Sleep Disorders Research Program Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.